AIMS: A postmarketing Prescription-Event Monitoring study was undertaken to monitor the safety of rofecoxib, a cyclo-oxygenase (COX)-2 selective inhibitor prescribed in primary care in England. METHODS: Questionnaires requesting clinical event data were sent to prescribing physicians between February and November 2000, and the data analysed for all events. RESULTS: There were 15,268 patients identified, mean age 62 years, 67% female. The commonest specified indication was osteoarthritis (24%). Dyspepsia and nausea were the most frequently reported adverse events. A history of dyspeptic or upper gastrointestinal (GI) conditions, recent use of other nonsteroidal anti-inflammatory drugs (NSAIDs), use of selected concomitant gastroirritant drugs (NSAIDs, aspirin, anticoagulants, antiplatelet drugs), or gastroprotective drugs (misoprostol, antacids, proton-pump inhibitors, histamine-2 antagonists), and age (>/= 65 years) modified the risk of having minor GI events. During treatment or within 1 month of stopping, 110 serious GI events were reported (including 76 upper GI bleeds/peptic ulcers, one perforated colon), 101 thromboembolic events, three reports of acute renal failure, one each of Stevens-Johnson syndrome, severe anaphylaxis and angio-oedema. CONCLUSIONS: Doctors should continue to prescribe NSAIDs including COX-2 selective inhibitors with caution.
AIMS: A postmarketing Prescription-Event Monitoring study was undertaken to monitor the safety of rofecoxib, a cyclo-oxygenase (COX)-2 selective inhibitor prescribed in primary care in England. METHODS: Questionnaires requesting clinical event data were sent to prescribing physicians between February and November 2000, and the data analysed for all events. RESULTS: There were 15,268 patients identified, mean age 62 years, 67% female. The commonest specified indication was osteoarthritis (24%). Dyspepsia and nausea were the most frequently reported adverse events. A history of dyspeptic or upper gastrointestinal (GI) conditions, recent use of other nonsteroidal anti-inflammatory drugs (NSAIDs), use of selected concomitant gastroirritant drugs (NSAIDs, aspirin, anticoagulants, antiplatelet drugs), or gastroprotective drugs (misoprostol, antacids, proton-pump inhibitors, histamine-2 antagonists), and age (>/= 65 years) modified the risk of having minor GI events. During treatment or within 1 month of stopping, 110 serious GI events were reported (including 76 upper GI bleeds/peptic ulcers, one perforated colon), 101 thromboembolic events, three reports of acute renal failure, one each of Stevens-Johnson syndrome, severe anaphylaxis and angio-oedema. CONCLUSIONS: Doctors should continue to prescribe NSAIDs including COX-2 selective inhibitors with caution.
Authors: L Laine; S Harper; T Simon; R Bath; J Johanson; H Schwartz; S Stern; H Quan; J Bolognese Journal: Gastroenterology Date: 1999-10 Impact factor: 22.682
Authors: Lois La Grenade; Lauren Lee; Joyce Weaver; Renan Bonnel; Claudia Karwoski; Laura Governale; Allen Brinker Journal: Drug Saf Date: 2005 Impact factor: 5.606
Authors: Amy Downing; Jacob Jacobsen; Henrik T Sorensen; Joseph K McLaughlin; Soren P Johnsen Journal: Br J Clin Pharmacol Date: 2006-08-30 Impact factor: 4.335
Authors: Deborah Layton; Patrick C Souverein; Eibert R Heerdink; Saad A W Shakir; Antoine C G Egberts Journal: Drug Saf Date: 2008 Impact factor: 5.606